מדינה: הממלכה המאוחדת
שפה: אנגלית
מקור: MHRA (Medicines & Healthcare Products Regulatory Agency)
Trastuzumab
Napp Pharmaceuticals Ltd
L01XC03
Trastuzumab
150mg
Powder for solution for infusion
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 08010500; GTIN: 8806238000315
1 PACKAGE LEAFLET: INFORMATION FOR THE USER HERZUMA 150 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION trastuzumab This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Herzuma is and what it is used for 2. What you need to know before you use Herzuma 3. How to use Herzuma 4. Possible side effects 5. How to store Herzuma 6. Contents of the pack and other information 1. WHAT HERZUMA IS AND WHAT IT IS USED FOR Herzuma contains the active substance trastuzumab, which is a monoclonal antibody. Monoclonal antibodies attach to specific proteins or antigens. Trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 (HER2). HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When Herzuma binds to HER2 it stops the growth of such cells and causes them to die. Your doctor may prescribe Herzuma for the treatment of breast and gastric cancer when: you have early breast cancer, with high levels of a protein called HER2. you have metastatic breast cancer (breast cancer that has spread beyond the original tumour) with high levels of HER2. Herzuma may be prescribed in combination with the chemotherapy medicine paclitaxel or docetaxel as first treatment for metastatic breast cancer or it may be prescribed alone if other treatments have proved unsuccessful. It is also used in combination with medicines called aromatase inhi קרא את המסמך השלם
OBJECT 1 HERZUMA 150 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION Summary of Product Characteristics Updated 10-Apr-2018 | Napp Pharmaceuticals Limited This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. Name of the medicinal product Herzuma 150 mg powder for concentrate for solution for infusion 2. Qualitative and quantitative composition One vial contains 150 mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity and ion exchange chromatography including specific viral inactivation and removal procedures. The reconstituted Herzuma solution contains 21 mg/mL of trastuzumab. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Powder for concentrate for solution for infusion. White to pale yellow lyophilised powder. 4. Clinical particulars 4.1 Therapeutic indications Breast cancer _Metastatic breast cancer _ Herzuma is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments. - in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. - in combination with an aromatase inhibitor for the treatment of postmenopausal pat קרא את המסמך השלם